Literature DB >> 25818622

A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants.

Cynthia K Y Ho1, Matthijs R A Welkers2, Xiomara V Thomas3, James C Sullivan4, Tara L Kieffer5, Henk W Reesink6, Sjoerd P H Rebers7, Menno D de Jong8, Janke Schinkel9, Richard Molenkamp10.   

Abstract

We compared 454 amplicon sequencing with clonal sequencing for the characterization of intra-host hepatitis C virus (HCV) NS3 variants. Clonal and 454 sequences were obtained from 12 patients enrolled in a clinical phase I study for telaprevir, an NS3-4a protease inhibitor. Thirty-nine datasets were used to compare the consensus sequence, average pairwise distance, normalized Shannon entropy, phylogenetic tree topology and the number and frequency of variants derived from both sequencing techniques. In general, a good concordance was observed between both techniques for the majority of datasets. Discordant results were observed for 5 out of 39 clonal and 454 datasets, which could be attributed to primer-related selective amplification used for clonal sequencing. Both 454 and clonal datasets consisted of a few major variants and a large number of low-frequency variants. Telaprevir resistance-associated variants were observed in low frequencies and were detected more often by 454. We conclude that performance of 454 and clonal sequencing is comparable for the characterization of intra-host virus populations. Not surprisingly, 454 is superior for the detection of low frequency resistance-associated variants. However, despite the greater coverage, 454 failed to detect some low frequency variants detected by clonal sequencing.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  454 sequencing; Clonal sequencing; Hepatitis C virus; NS3; Next-generation sequencing; Telaprevir; Viral variants

Mesh:

Substances:

Year:  2015        PMID: 25818622     DOI: 10.1016/j.jviromet.2015.03.018

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  4 in total

1.  Characterization of Hepatitis C Virus (HCV) Envelope Diversification from Acute to Chronic Infection within a Sexually Transmitted HCV Cluster by Using Single-Molecule, Real-Time Sequencing.

Authors:  Cynthia K Y Ho; Jayna Raghwani; Sylvie Koekkoek; Richard H Liang; Jan T M Van der Meer; Marc Van Der Valk; Menno De Jong; Oliver G Pybus; Janke Schinkel; Richard Molenkamp
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

Review 2.  Virologic Tools for HCV Drug Resistance Testing.

Authors:  Slim Fourati; Jean-Michel Pawlotsky
Journal:  Viruses       Date:  2015-12-04       Impact factor: 5.048

3.  Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

Authors:  Heiner Wedemeyer; Xavier Forns; Christophe Hézode; Samuel S Lee; Astrid Scalori; Athina Voulgari; Sophie Le Pogam; Isabel Nájera; James A Thommes
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

4.  Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay.

Authors:  Hope R Lapointe; Weiyan Dong; Winnie W Y Dong; Don Kirkby; Conan Woods; Art F Y Poon; Anita Y M Howe; P Richard Harrigan; Chanson J Brumme
Journal:  Viruses       Date:  2021-08-30       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.